![Holger Neecke](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Holger Neecke
Vorstandsvorsitzender bei Tethis SpA
Aktive Positionen von Holger Neecke
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Tethis SpA
![]() Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Vorstandsvorsitzender | 20.10.2022 | - |
Karriereverlauf von Holger Neecke
Ehemalige bekannte Positionen von Holger Neecke
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ABLYNX | Corporate Officer/Principal | - | - |
MOLMED S.P.A. | Investor Relations Kontakt | 01.10.2001 | - |
Public Communications Contact | 07.07.2010 | - |
Ausbildung von Holger Neecke
University of Milan | Doctorate Degree |
University of Basel | Undergraduate Degree |
University of Bocconi | Masters Business Admin |
Statistik
International
Italien | 5 |
Schweiz | 2 |
Belgien | 2 |
Operativ
Investor Relations Contact | 1 |
Public Communications Contact | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
AGC Biologics SpA
![]() AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Ablynx NV
![]() Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Tethis SpA
![]() Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Health Technology |
- Börse
- Insiders
- Holger Neecke
- Erfahrung